{
  "meta": {
    "id": "test10",
    "title": "Mood Disorders (Depressive Disorders)",
    "category": "Subject Wise / Mixed"
  },
  "questions": [
    {
      "text": "All of the following statements are correct about depression EXCEPT:",
      "options": [
        {
          "label": "A",
          "text": "Depression is the most common psychiatric disorder in the world.",
          "correct": true
        },
        {
          "label": "B",
          "text": "Females have a higher lifetime risk of developing depression compared to males.",
          "correct": false
        },
        {
          "label": "C",
          "text": "Depression is the most common cause of suicide.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Excluding tobacco use disorder, depression is the most common psychiatric disorder in India.",
          "correct": false
        }
      ],
      "correct_answer": "A. Depression is the most common psychiatric disorder in the world.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Depression is the most common psychiatric disorder in the world.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B. Females have a higher lifetime risk of developing depression compared to males: This is correct . Depression is more common in females than males.</li><li>\u2022 Option B. Females have a higher lifetime risk of developing depression compared to males:</li><li>\u2022 correct</li><li>\u2022 Option C. Depression is the most common cause of suicide: This statement is correct .</li><li>\u2022 Option C. Depression is the most common cause of suicide:</li><li>\u2022 correct</li><li>\u2022 Option D. Excluding tobacco use disorder, depression is the most common psychiatric disorder in India: According to the National Mental Health Survey (NMHS) conducted by the National Institute of Mental Health and Neurosciences (NIMHANS) in India , the most common psychiatric disorder in India is depression , with a lifetime prevalence of 5.3%. However, if we specifically consider tobacco use disorder as a separate category, the prevalence is much higher. The NMHS found that the prevalence of current tobacco use in India was 28.6%, making it the most common substance use disorder in the country</li><li>\u2022 Option D. Excluding tobacco use disorder, depression is the most common psychiatric disorder in India:</li><li>\u2022 National Mental Health Survey</li><li>\u2022 conducted by the National Institute of Mental Health and Neurosciences</li><li>\u2022 India</li><li>\u2022 most common psychiatric disorder in India is depression</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 While depression is a prevalent and disabling condition worldwide , anxiety disorders as a group may have a higher overall prevalence.</li><li>\u27a4 While depression is a prevalent</li><li>\u27a4 disabling condition worldwide</li><li>\u27a4 anxiety disorders as a group</li><li>\u27a4 higher overall prevalence.</li><li>\u27a4 Ref : Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 393.</li><li>\u27a4 Ref : Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 393.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7b808175",
      "audio": ""
    },
    {
      "text": "A 30-year-old female patient in her 2nd trimester of her second pregnancy presents with a 6-week history of persistent low mood, anhedonia, insomnia, and feelings of worthlessness. She reports having experienced a similar episode during her first pregnancy, which improved significantly with the addition of an antidepressant. Her current pregnancy has been uncomplicated thus far. The psychiatrist initially tried a course of cognitive-behavioural therapy (CBT) for 4 weeks, but her symptoms have not improved. Consequently, the psychiatrist decides to initiate pharmacological treatment for her significant depressive symptoms. Which one of the following antidepressants would be the most appropriate choice for this patient?",
      "options": [
        {
          "label": "A",
          "text": "Fluoxetine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Sertraline",
          "correct": true
        },
        {
          "label": "C",
          "text": "Imipramine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Escitalopram",
          "correct": false
        }
      ],
      "correct_answer": "B. Sertraline",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Sertraline</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Fluoxetine and D. Escitalopram are SSRIs . But the placental exposure is more than that of Sertraline.</li><li>\u2022 Option A. Fluoxetine</li><li>\u2022 D. Escitalopram</li><li>\u2022 SSRIs</li><li>\u2022 Option C. Imipramine , a tricyclic antidepressant , is less commonly used during pregnancy due to potential side effects and less favorable safety profile compared to SSRIs like sertraline.</li><li>\u2022 Option C. Imipramine</li><li>\u2022 tricyclic antidepressant</li><li>\u2022 less commonly used during pregnancy</li><li>\u2022 potential side effects and less favorable safety profile</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Sertraline is often the preferred choice for the pharmacological treatment of depression during pregnancy due to its relatively favorable safety profile and effectiveness . While other SSRIs like fluoxetine and escitalopram are also used , sertraline is preferred based on less placental exposure . Tricyclic antidepressants like imipramine are less commonly used due to their side effect profile.</li><li>\u27a4 Sertraline</li><li>\u27a4 preferred choice for the pharmacological treatment of depression</li><li>\u27a4 pregnancy due to its relatively favorable safety profile</li><li>\u27a4 effectiveness</li><li>\u27a4 SSRIs like fluoxetine</li><li>\u27a4 escitalopram are also used</li><li>\u27a4 sertraline</li><li>\u27a4 preferred based on less placental exposure</li><li>\u27a4 Tricyclic antidepressants</li><li>\u27a4 imipramine are less commonly used</li><li>\u27a4 Ref : Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 390-391.</li><li>\u27a4 Ref :</li><li>\u27a4 Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 390-391.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "27e1c3ff",
      "audio": ""
    },
    {
      "text": "A 40-year-old male with a history of recurrent depressive disorder presents to the clinic with symptoms of depression that began 8 weeks ago. His past medical history is significant for two previous episodes of major depression in the past five years, both of which were managed with a combination of pharmacotherapy and psychotherapy. He reports a gradual increase in the severity of his symptoms over the past two months, characterized by a persistent low mood, anhedonia, insomnia, and feelings of guilt and worthlessness. His appetite has also decreased, and he has lost 5 kg during this period. The patient's family reports that he has become increasingly socially withdrawn and has stopped engaging in his usual hobbies. Three days ago, he attempted suicide and was about to hang himself, but was saved by a family member who intervened just before the attempt was made. The patient is currently not receiving any treatment. What is the next best step in the management of this patient?",
      "options": [
        {
          "label": "A",
          "text": "Start fluoxetine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Start cognitive-behavioral therapy (CBT) sessions",
          "correct": false
        },
        {
          "label": "C",
          "text": "Offer electroconvulsive therapy (ECT)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Start fluoxetine for 4 weeks, and in case of no improvement, offer ECT",
          "correct": false
        }
      ],
      "correct_answer": "C. Offer electroconvulsive therapy (ECT)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Offer electroconvulsive therapy (ECT)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation :</li><li>\u2022 Option A. Starting fluoxetine or B. initiating CBT sessions may eventually be beneficial for the patient , but they are less likely to provide the rapid symptom relief needed in this urgent situation.</li><li>\u2022 Option A. Starting fluoxetine or B. initiating CBT sessions</li><li>\u2022 eventually be beneficial for the patient</li><li>\u2022 less likely to provide the rapid symptom relief</li><li>\u2022 Option D. Starting SSRIs for 4 weeks and offering ECT only if there is no improvement , delays the potential benefits of ECT and may not adequately address the immediate risk of another suicide attempt.</li><li>\u2022 Option D. Starting SSRIs for 4 weeks and offering ECT only if there is no improvement</li><li>\u2022 delays the potential benefits of ECT</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In severe cases of depression , particularly when accompanied by suicidal ideation and lack of response to medication , ECT is often the most effective and rapid treatment . ECT is indicated when there is a need for a quick and robust response, especially when there is a high risk of suicide.</li><li>\u27a4 severe cases of depression</li><li>\u27a4 suicidal ideation and lack of response to medication</li><li>\u27a4 ECT</li><li>\u27a4 most effective and rapid treatment</li><li>\u27a4 Ref : Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 393.</li><li>\u27a4 Ref : Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 393.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "957edd61",
      "audio": ""
    },
    {
      "text": "A 38-year-old female presents with a 3-month history of symptoms characterized by persistent low mood, anhedonia, fatigue, difficulty concentrating, and feelings of worthlessness. Over the last two weeks, she has started hearing a scary voice telling her, \"You are a bad woman and will be punished.\" What is the preferred treatment for this patient?",
      "options": [
        {
          "label": "A",
          "text": "Fluoxetine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Fluoxetine plus risperidone",
          "correct": true
        },
        {
          "label": "C",
          "text": "Olanzapine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Cognitive-behavioral therapy (CBT)",
          "correct": false
        }
      ],
      "correct_answer": "B. Fluoxetine plus risperidone",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Fluoxetine plus risperidone</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Fluoxetine alone, may be effective for treating the depressive symptoms but would not address the psychotic symptoms.</li><li>\u2022 Option A. Fluoxetine</li><li>\u2022 may be effective for treating the depressive symptoms</li><li>\u2022 not address the psychotic symptoms.</li><li>\u2022 Option C. Olanzapine is an atypical antipsychotic and would target the psychotic symptoms but may not be sufficient for treating the depressive symptoms.</li><li>\u2022 Option C. Olanzapine</li><li>\u2022 atypical antipsychotic</li><li>\u2022 would target the psychotic symptoms</li><li>\u2022 Option D. Cognitive-behavioral therapy (CBT) could be a helpful adjunctive treatment for managing the depressive symptoms , but it is not the primary treatment choice in this case due to the presence of psychotic features.</li><li>\u2022 Option D. Cognitive-behavioral therapy (CBT)</li><li>\u2022 helpful adjunctive treatment for managing the depressive symptoms</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 For patients with major depressive disorder with psychotic features , the preferred treatment often involves a combination of an antidepressant and an antipsychotic to effectively address both the depressive and psychotic symptoms . Fluoxetine can treat the depressive symptoms, while risperidone can manage the psychotic symptoms.</li><li>\u27a4 major depressive disorder with psychotic features</li><li>\u27a4 preferred treatment</li><li>\u27a4 involves a combination of an antidepressant</li><li>\u27a4 antipsychotic to effectively address both the depressive and psychotic symptoms</li><li>\u27a4 Ref : Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 390-391.</li><li>\u27a4 Ref :</li><li>\u27a4 Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 390-391.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "58b94e50",
      "audio": ""
    },
    {
      "text": "The neurobiological changes in depression are characterized by which of the following statements? Decreased activity in the prefrontal cortex Increased activity in the prefrontal cortex Decreased activity in the amygdala Increased activity in the amygdala",
      "options": [
        {
          "label": "A",
          "text": "1 and 3 are correct",
          "correct": false
        },
        {
          "label": "B",
          "text": "1 and 4 are correct",
          "correct": true
        },
        {
          "label": "C",
          "text": "2 and 3 are correct",
          "correct": false
        },
        {
          "label": "D",
          "text": "2 and 4 are correct",
          "correct": false
        }
      ],
      "correct_answer": "B. 1 and 4 are correct",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) 1 and 4 are correct</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 2. Increased activity in the prefrontal cortex: This statement is generally incorrect in the context of depression. As mentioned, decreased rather than increased activity is typically observed in the prefrontal cortex in depressed patients.</li><li>\u2022 2. Increased activity in the prefrontal cortex:</li><li>\u2022 incorrect</li><li>\u2022 3. Decreased activity in the amygdala: This statement is incorrect for depression. Increased, rather than decreased, activity in the amygdala is often associated with depression, related to the enhanced processing of negative emotions.</li><li>\u2022 3. Decreased activity in the amygdala:</li><li>\u2022 incorrect</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Neurobiological changes in depression typically include decreased activity in the prefrontal cortex , which is associated with impaired cognitive and emotional regulation , and increased activity in the amygdala , which is related to heightened negative emotional processing.</li><li>\u27a4 Neurobiological changes</li><li>\u27a4 depression</li><li>\u27a4 decreased activity in the prefrontal cortex</li><li>\u27a4 associated with impaired cognitive</li><li>\u27a4 emotional regulation</li><li>\u27a4 increased activity in the amygdala</li><li>\u27a4 Ref : Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 396.</li><li>\u27a4 Ref :</li><li>\u27a4 Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 396.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b41b6b2e",
      "audio": ""
    },
    {
      "text": "A 28-year-old patient presents with sadness of mood, frequent crying spells, insomnia, occasional suicidal thoughts, and lack of energy. The psychiatrist decides to start him on antidepressants, but the patient mentions that he is about to get married in one month and is concerned about the potential sexual side effects of the medication. Which of the following antidepressants should be prescribed to this patient?",
      "options": [
        {
          "label": "A",
          "text": "Sertraline",
          "correct": false
        },
        {
          "label": "B",
          "text": "Venlafaxine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Mirtazapine",
          "correct": true
        },
        {
          "label": "D",
          "text": "Escitalopram",
          "correct": false
        }
      ],
      "correct_answer": "C. Mirtazapine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Mirtazapine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Sertraline is a selective serotonin reuptake inhibitor (SSRI) that is commonly used to treat depression . However, SSRIs are known to cause sexual side effects such as decreased libido, delayed ejaculation, and poor erection in some patients.</li><li>\u2022 Option A. Sertraline</li><li>\u2022 selective serotonin reuptake inhibitor</li><li>\u2022 used to treat depression</li><li>\u2022 Option B. Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) used to treat depression. While SNRIs are also effective in treating depression, they may cause similar sexual side effects as SSRIs due to their effect on serotonin.</li><li>\u2022 Option B. Venlafaxine</li><li>\u2022 serotonin-norepinephrine reuptake inhibitor</li><li>\u2022 treat depression.</li><li>\u2022 Option D. Escitalopram is another SSRI used to treat depression. Like sertraline, it may cause sexual side effects due to its impact on serotonin.</li><li>\u2022 Option D. Escitalopram</li><li>\u2022 SSRI used to treat depression.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Mirtazapine belongs to a class called NSSA (nor adrenergic and specific serotonergic antidepressant). The mechanism of action is antagonism of central presynaptic a2 (alpha2) receptors which results in increased firing of norepinephrine and serotonin neurons . The other important action is antagonism of postsynaptic serotonin 5 HT2 and 5 HT3 receptors. Mirtazapine causes sedation and weight gain but doesn't have problematic sexual side effects . Other side effects include dry mouth, constipation, myalgia and disturbing dreams.</li><li>\u27a4 Mirtazapine belongs to a class called NSSA</li><li>\u27a4 The mechanism of action is antagonism of central presynaptic a2</li><li>\u27a4 receptors which results in increased firing of norepinephrine and serotonin neurons</li><li>\u27a4 doesn't have problematic sexual side effects</li><li>\u27a4 Ref : Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 637.</li><li>\u27a4 Ref :</li><li>\u27a4 Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 637.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9b4e1e6c",
      "audio": ""
    },
    {
      "text": "A 45-year-old male with treatment-resistant major depressive disorder presents to the clinic. Despite multiple trials of various medications and cognitive-behavioral therapy, his depressive symptoms have persisted. His psychiatrist is considering the use of esketamine as an adjunctive treatment. Which of the following statements is true regarding the use of esketamine for this patient?",
      "options": [
        {
          "label": "A",
          "text": "Esketamine is administered orally as an adjunctive treatment",
          "correct": false
        },
        {
          "label": "B",
          "text": "Esketamine is administered intravenously as an adjunctive treatment",
          "correct": false
        },
        {
          "label": "C",
          "text": "Esketamine is administered intranasally as an adjunctive treatment",
          "correct": true
        },
        {
          "label": "D",
          "text": "Esketamine is contraindicated in patients with a history of substance abuse",
          "correct": false
        }
      ],
      "correct_answer": "C. Esketamine is administered intranasally as an adjunctive treatment",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Esketamine is administered intranasally as an adjunctive treatment</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A . is incorrect , as esketamine is not administered orally.</li><li>\u2022 Option A</li><li>\u2022 incorrect</li><li>\u2022 Option B . is incorrect because esketamine is not administered intravenously.</li><li>\u2022 Option B</li><li>\u2022 incorrect</li><li>\u2022 Option D . is also incorrect , as esketamine is not contraindicated in patients with a history of substance abuse, although caution and monitoring are advised in such cases.</li><li>\u2022 Option D</li><li>\u2022 incorrect</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Esketamine is approved for use as an adjunctive treatment for treatment-resistant major depressive disorder in adults and is administered intranasally . It offers a novel treatment option for patients who have not responded to other antidepressant therapies.</li><li>\u27a4 Esketamine</li><li>\u27a4 approved for use as an adjunctive treatment</li><li>\u27a4 treatment-resistant major depressive disorder</li><li>\u27a4 adults and is administered intranasally</li><li>\u27a4 Ref : Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 648.</li><li>\u27a4 Ref :</li><li>\u27a4 Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 648.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "824299c8",
      "audio": ""
    },
    {
      "text": "A 32-year-old female with a history of major depressive disorder has not responded adequately to trials of multiple antidepressant medications and cognitive-behavioral therapy. Her psychiatrist is considering other treatment options and discusses repetitive transcranial magnetic stimulation (rTMS) with the patient. Which of the following statements is true regarding the use of rTMS for this patient?",
      "options": [
        {
          "label": "A",
          "text": "rTMS is considered more effective than ECT in the treatment of depression",
          "correct": false
        },
        {
          "label": "B",
          "text": "rTMS is an invasive procedure, however, does not require the use of anesthetic agents",
          "correct": false
        },
        {
          "label": "C",
          "text": "rTMS can cause seizures as a side effect",
          "correct": true
        },
        {
          "label": "D",
          "text": "rTMS is a noninvasive procedure and there is no risk of seizures with rTMS",
          "correct": false
        }
      ],
      "correct_answer": "C. rTMS can cause seizures as a side effect",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) rTMS can cause seizures as a side effect</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive procedure used in the treatment of major depressive disorder, especially in cases resistant to medications and psychotherapy. It uses rapidly changing magnetic fields to produce small electric currents (known as eddy currents) in superficial cortical neurons. It is non-convulsive, no anesthesia required. While generally safe, rTMS does carry a rare but serious risk of inducing seizures. It is not considered more effective than ECT and does not require anesthesia, distinguishing it as a less invasive alternative.</li><li>\u27a4 Ref : Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 737.</li><li>\u27a4 Ref</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a82ad159",
      "audio": ""
    },
    {
      "text": "A 21-year-old female presents to her psychiatrist with a history of depressive symptoms, including persistent sadness, anhedonia, fatigue, and difficulty concentrating. She was previously started on sertraline, which led to significant improvement in her symptoms. However, she discontinued the medication due to distressing side effects, including loss of sexual desire and weight gain. The psychiatrist is considering switching her to another antidepressant that would be less likely to cause these side effects. Which of the following antidepressants would be the most appropriate choice for this patient?",
      "options": [
        {
          "label": "A",
          "text": "Bupropion",
          "correct": true
        },
        {
          "label": "B",
          "text": "Mirtazapine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Venlafaxine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Fluoxetine",
          "correct": false
        }
      ],
      "correct_answer": "A. Bupropion",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Bupropion</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation :</li><li>\u2022 Option B. Mirtazapine is an atypical antidepressant that is commonly associated with weight gain and increased appetite . Although mirtazapine is less likely to cause sexual side effects, the high likelihood of weigh gain rules it out in this patient.</li><li>\u2022 Option B. Mirtazapine</li><li>\u2022 atypical antidepressant that is commonly associated with weight gain and increased appetite</li><li>\u2022 Option C. Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI). It can cause both sexual side effects as well as weight gain similar to those experienced with sertraline.</li><li>\u2022 Option C. Venlafaxine</li><li>\u2022 serotonin-norepinephrine reuptake inhibitor</li><li>\u2022 Option D. Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) like sertraline and can cause both weight gain and loss of sexual desire.</li><li>\u2022 Option D. Fluoxetine</li><li>\u2022 selective serotonin reuptake inhibitor</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 For patients experiencing distressing sexual side effects and weight gain from SSRIs , bupropion is an appropriate alternative antidepressant due to its lower likelihood of causing these specific side effects .</li><li>\u27a4 patients experiencing distressing sexual side effects</li><li>\u27a4 weight gain from SSRIs</li><li>\u27a4 bupropion</li><li>\u27a4 appropriate alternative antidepressant</li><li>\u27a4 lower likelihood of causing these specific side effects</li><li>\u27a4 Ref : Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 635-637.</li><li>\u27a4 Ref : Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 635-637.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "48d576c8",
      "audio": ""
    },
    {
      "text": "A 29-year-old male teacher presents to his primary care physician with a 4-year history of depressive symptoms. He reports feeling constantly down and having low energy, with occasional trouble concentrating and making decisions. His sleep and appetite disturbances are also occasional. Despite his symptoms, the patient continues to go to work regularly. He notes that when he is with other people, he sometimes feels better, but mostly he feels low. The patient's symptoms have been persistent but relatively stable over the past four years. Based on the patient's clinical presentation, which of the following diagnoses is most likely?",
      "options": [
        {
          "label": "A",
          "text": "Major Depressive Disorder",
          "correct": false
        },
        {
          "label": "B",
          "text": "Bipolar Disorder",
          "correct": false
        },
        {
          "label": "C",
          "text": "Persistent Depressive Disorder (Dysthymia)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Generalized Anxiety Disorder",
          "correct": false
        }
      ],
      "correct_answer": "C. Persistent Depressive Disorder (Dysthymia)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Persistent Depressive Disorder (Dysthymia)</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Persistent Depressive Disorder (Dysthymia) is the presence of mild depressive symptoms (not enough to diagnose a major depressive episode) for a period of more than two years (and at least one year in children and adolescents). While the symptoms might not be as severe as those in major depressive disorder, they are chronic and persistent.</li><li>\u27a4 Persistent Depressive Disorder</li><li>\u27a4 presence of mild depressive symptoms</li><li>\u27a4 period of more than two years</li><li>\u27a4 Ref : Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 382.</li><li>\u27a4 Ref :</li><li>\u27a4 Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 382.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "efc4c788",
      "audio": ""
    },
    {
      "text": "A 29-year-old woman presents to her primary care physician with complaints of persistent low mood, difficulty sleeping, and feelings of worthlessness for the past 6 months. She reports that these symptoms have interfered with her daily activities and have negatively affected her relationships. Her medical history is unremarkable, and she is not currently on any medication. The patient mentions that she and her partner are planning to conceive a baby in the near future. The physician is considering recommending a treatment option for her depressive symptoms. Which of the following treatment options is most appropriate for this patient?",
      "options": [
        {
          "label": "A",
          "text": "Regular exercise",
          "correct": false
        },
        {
          "label": "B",
          "text": "Counseling",
          "correct": false
        },
        {
          "label": "C",
          "text": "Cognitive-behavioral therapy (CBT)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Selective serotonin reuptake inhibitor (SSRI) antidepressant",
          "correct": false
        }
      ],
      "correct_answer": "C. Cognitive-behavioral therapy (CBT)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Cognitive-behavioural therapy (CBT).</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Regular exercise is beneficial for mental health and can be recommended as an adjunctive treatment for mild to moderate depression . However, given the severity and duration of the patient's symptoms, exercise alone might not be sufficient as the sole treatment.</li><li>\u2022 Option A. Regular exercise</li><li>\u2022 mental health</li><li>\u2022 adjunctive treatment</li><li>\u2022 mild to moderate depression</li><li>\u2022 Option B. Counseling can be helpful for individuals with depression , and it may involve various therapeutic approaches, including supportive therapy . However, CBT is a more structured form of psychotherapy with a strong evidence base for the treatment of depression, making it a preferred option in this scenario.</li><li>\u2022 Option B. Counseling</li><li>\u2022 helpful for individuals with depression</li><li>\u2022 involve various therapeutic approaches,</li><li>\u2022 supportive therapy</li><li>\u2022 Option D. Selective serotonin reuptake inhibitor (SSRI) antidepressants are effective for treating depression , but their use in women who are planning to conceive requires careful consideration due to potential risks during pregnancy . If non-pharmacological treatments like CBT are effective, they may be preferred to avoid potential medication-related risks during preconception and pregnancy.</li><li>\u2022 Option D. Selective serotonin reuptake inhibitor (SSRI) antidepressants</li><li>\u2022 effective for treating depression</li><li>\u2022 use in women who are planning to conceive requires careful consideration due to potential risks during pregnancy</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 For individuals with depression , especially those planning pregnancy , Cognitive-behavioral therapy (CBT) is an effective and safe initial treatment option . CBT provides a non-pharmacological approach to manage depressive symptoms and does not carry the potential risks associated with medication use during preconception and pregnancy.</li><li>\u27a4 individuals with depression</li><li>\u27a4 especially those planning pregnancy</li><li>\u27a4 Cognitive-behavioral therapy</li><li>\u27a4 effective and safe initial treatment option</li><li>\u27a4 Ref : Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 392.</li><li>\u27a4 Ref :</li><li>\u27a4 Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 392.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "60d05448",
      "audio": ""
    },
    {
      "text": "A 34-year-old woman presents to the outpatient clinic with persistent feelings of sadness over the past six months. She describes her mood as \"consistently low\" and admits to having lost interest in activities she once enjoyed. She often feels tired and has trouble sleeping. When asked about her thought patterns, she describes feeling \"worthless,\" believes that \"everything is against her,\" and fears \"nothing will ever get better.\" Based on her described thought patterns, which of the following is NOT part of the cognitive triad as described by Beck?",
      "options": [
        {
          "label": "A",
          "text": "Negative views of the future",
          "correct": false
        },
        {
          "label": "B",
          "text": "Negative views of self",
          "correct": false
        },
        {
          "label": "C",
          "text": "Helplessness",
          "correct": false
        },
        {
          "label": "D",
          "text": "Guilt",
          "correct": true
        }
      ],
      "correct_answer": "D. Guilt",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/03/12/screenshot-2024-03-12-111632.jpg"
      ],
      "explanation": "<p><strong>Ans. D) Guilt</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Aaron Beck's cognitive triad is a model used to describe the thought patterns frequently seen in patients with depression . According to this triad, individuals with depression have:</li><li>\u2022 Aaron Beck's cognitive triad</li><li>\u2022 model used to describe the thought patterns frequently seen in patients with depression</li><li>\u2022 Option A: Negative views of the future: They often feel hopeless and believe that their situation won't improve.</li><li>\u2022 Option A: Negative views of the future:</li><li>\u2022 feel hopeless</li><li>\u2022 believe that their situation won't improve.</li><li>\u2022 Option B: Negative views of self: This can manifest as feelings of worthlessness, self-blame , or inadequacy.</li><li>\u2022 Option B: Negative views of self:</li><li>\u2022 manifest as feelings of worthlessness, self-blame</li><li>\u2022 Option C: Helplessness: They feel that there is nothing they can do to change the negative situations in their lives.</li><li>\u2022 Option C: Helplessness:</li><li>\u2022 there is nothing they can do to change the negative situations</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 The cognitive theory of depression was proposed by Aaron T Beck . According to this theory, negative thoughts have a central role in the development of depression . Beck proposed that there are three central thoughts/ideas in depression , the so-called cognitive triad of depression .</li><li>\u2022 cognitive theory of depression</li><li>\u2022 Aaron T Beck</li><li>\u2022 negative thoughts have a central role in the development of depression</li><li>\u2022 three central thoughts/ideas in depression</li><li>\u2022 so-called cognitive triad</li><li>\u2022 depression</li><li>\u2022 Ref : Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 399.</li><li>\u2022 Ref :</li><li>\u2022 Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 399.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "cf562698",
      "audio": ""
    },
    {
      "text": "A 45-year-old woman seeks help after experiencing symptoms of depressed mood, diminished appetite, difficulty sleeping, persistent fatigue, and a general disinterest in her surroundings for the past year. She mentions these feelings began after she faced a personal problem 12 months ago. What is the most probable diagnosis for her condition?",
      "options": [
        {
          "label": "A",
          "text": "Adjustment disorder",
          "correct": false
        },
        {
          "label": "B",
          "text": "Conversion disorder",
          "correct": false
        },
        {
          "label": "C",
          "text": "Major depressive disorder",
          "correct": true
        },
        {
          "label": "D",
          "text": "Malingering",
          "correct": false
        }
      ],
      "correct_answer": "C. Major depressive disorder",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/03/12/screenshot-2024-03-12-112048.jpg"
      ],
      "explanation": "<p><strong>Ans. C) Major depressive disorder</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A: Adjustment Disorder: While adjustment disorders involve emotional or behavioral symptoms in response to a stressor , these symptoms typically occur within three months of the stressor and tend to resolve within six months after the stressor or its consequences have ended. The duration and nature of her symptoms extend beyond the typical scope of an adjustment disorder . It does not meet the criteria of MDD.</li><li>\u2022 Option A: Adjustment Disorder:</li><li>\u2022 emotional or behavioral symptoms in response to a stressor</li><li>\u2022 occur within three months of the stressor and tend to resolve within six months after the stressor</li><li>\u2022 duration</li><li>\u2022 nature of her symptoms extend beyond the typical scope</li><li>\u2022 adjustment disorder</li><li>\u2022 Option B: Conversion Disorder: This involves neurological symptoms that are incompatible with neurological pathways and cannot be explained by a medical or neurological condition. There is no indication in the scenario of such symptoms.</li><li>\u2022 Option B: Conversion Disorder:</li><li>\u2022 neurological symptoms</li><li>\u2022 incompatible with neurological pathways</li><li>\u2022 Option D: Malingering: This involves the intentional production of false or grossly exaggerated physical or psychological symptoms , motivated by external incentives such as avoiding work or obtaining financial compensation . There is no indication in the scenario to suggest malingering.</li><li>\u2022 Option D: Malingering:</li><li>\u2022 intentional production of false or grossly exaggerated physical or psychological symptoms</li><li>\u2022 external incentives such as avoiding work or obtaining financial compensation</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Ref : Ka plan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 381 .</li><li>\u2022 Ref :</li><li>\u2022 Ka plan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 381</li><li>\u2022 Ka</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1f65a487",
      "audio": ""
    },
    {
      "text": "A 30-year-old male presents to the psychiatric clinic reporting persistent sadness, lack of interest in activities, decreased sleep, and appetite over the past 6 months. Recently, he has started to experience \u201chearing of voices\u201d commanding him to \u2018kill himself\u2019. Based on this clinical presentation, what is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Schizophrenia",
          "correct": false
        },
        {
          "label": "B",
          "text": "Depression with psychotic symptoms",
          "correct": true
        },
        {
          "label": "C",
          "text": "Bipolar disorder (mixed episode)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Schizophreniform disorder",
          "correct": false
        }
      ],
      "correct_answer": "B. Depression with psychotic symptoms",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Depression with psychotic symptoms</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A: Schizophrenia is characterized by at least 6 months of continuous disturbance , with at least 1 month of active-phase symptoms, including two or more of the following: delusions, hallucinations, disorganized speech, disorganized or catatonic behavior , or negative symptoms . The patient\u2019s prominent mood symptoms and the duration of his condition make this less likely.</li><li>\u2022 Option A:</li><li>\u2022 Schizophrenia</li><li>\u2022 least 6 months of continuous disturbance</li><li>\u2022 at least 1 month of active-phase</li><li>\u2022 delusions, hallucinations, disorganized speech, disorganized or catatonic behavior</li><li>\u2022 negative symptoms</li><li>\u2022 Option C: Bipolar disorder (mixed episode) could present with depressive and manic symptoms concurrently , but the patient does not exhibit manic symptoms , making this option less likely.</li><li>\u2022 Option C:</li><li>\u2022 Bipolar disorder</li><li>\u2022 present with depressive and manic symptoms concurrently</li><li>\u2022 patient does not exhibit manic symptoms</li><li>\u2022 Option D: Schizophreniform disorder involves symptoms similar to schizophrenia but lasts for 1-6 months . Given the 6-month duration of this patient\u2019s symptoms, this is less likely.</li><li>\u2022 Option D:</li><li>\u2022 Schizophreniform</li><li>\u2022 symptoms similar to schizophrenia</li><li>\u2022 lasts for 1-6 months</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Psychotic depression is characterized by presence of depressive symptoms with delusions/hallucinations. Psychotic symptoms can be mood congruent/mood incongruent. If the content of delusions/hallucinations matches with the mood , it's called mood congruent , if it doesnt match , it's called mood incongruent . E.g. A patient with severe depression develops a delusion that the world is ending. It is an example of mood-congruent delusion.</li><li>\u27a4 Psychotic depression</li><li>\u27a4 presence of depressive symptoms with delusions/hallucinations.</li><li>\u27a4 mood congruent/mood incongruent.</li><li>\u27a4 content of delusions/hallucinations matches</li><li>\u27a4 mood</li><li>\u27a4 called mood congruent</li><li>\u27a4 doesnt match</li><li>\u27a4 mood incongruent</li><li>\u27a4 Ref : Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 380 .</li><li>\u27a4 Ref :</li><li>\u27a4 Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 380</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9a8a4342",
      "audio": ""
    },
    {
      "text": "A 45-year-old woman presents to the psychiatric clinic with a six-month history of severe depression. She reports persistent low mood, lack of pleasure in activities, and significant weight loss. During the clinical interview, she exhibits slowed speech and movement. Based on her presentation, which of the following is not characteristic of melancholic depression?",
      "options": [
        {
          "label": "A",
          "text": "Psychomotor agitation",
          "correct": false
        },
        {
          "label": "B",
          "text": "Profound guilt",
          "correct": false
        },
        {
          "label": "C",
          "text": "Initial insomnia",
          "correct": true
        },
        {
          "label": "D",
          "text": "Diurnal mood fluctuation",
          "correct": false
        }
      ],
      "correct_answer": "C. Initial insomnia",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Initial insomnia</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A: Psychomotor agitation , which includes restlessness and pacing, can be seen in melancholic depression.</li><li>\u2022 Option A:</li><li>\u2022 Psychomotor agitation</li><li>\u2022 restlessness and pacing,</li><li>\u2022 Option B: Profound guilt is a common symptom in melancholic depression , where individuals may experience excessive and inappropriate feelings of guilt and worthlessness.</li><li>\u2022 Option B:</li><li>\u2022 Profound guilt</li><li>\u2022 melancholic depression</li><li>\u2022 excessive and inappropriate feelings of guilt and worthlessness.</li><li>\u2022 Option D: Diurnal mood fluctuation , where mood is worse in the morning and improves as the day goes on , is characteristic of melancholic depression.</li><li>\u2022 Option D:</li><li>\u2022 Diurnal mood fluctuation</li><li>\u2022 mood is worse in the morning and improves as the day goes on</li><li>\u2022 melancholic depression.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Melancholic depression , also known as involutional melancholia is a type of Depression with melancholic features is usually seen in old age , and is characterised by the following features:</li><li>\u27a4 Melancholic depression</li><li>\u27a4 involutional melancholia is a type of Depression with melancholic features</li><li>\u27a4 old age</li><li>\u27a4 Prominent biological symptoms: Early morning awakening (waking up at least 2 hours before usual time) Significant anorexia and weight loss Significant psychomotor agitation or retardation Anhedonia and lack of mood reactivity (i.e. the patient's mood doesn't improve even if some positive event occurs) A distinct quality of intensely depressed mood , often referred to as a state of despondency or despair , also called as empty mood . The patients feels miserable. Depression is worse in the morning Excessive guilt.</li><li>\u27a4 Prominent biological symptoms: Early morning awakening (waking up at least 2 hours before usual time) Significant anorexia and weight loss</li><li>\u27a4 Early morning awakening (waking up at least 2 hours before usual time) Significant anorexia and weight loss</li><li>\u27a4 Early morning awakening (waking up at least 2 hours before usual time)</li><li>\u27a4 Early morning awakening</li><li>\u27a4 Significant anorexia and weight loss</li><li>\u27a4 anorexia and weight loss</li><li>\u27a4 Significant psychomotor agitation or retardation</li><li>\u27a4 Significant psychomotor agitation or retardation</li><li>\u27a4 Anhedonia and lack of mood reactivity (i.e. the patient's mood doesn't improve even if some positive event occurs)</li><li>\u27a4 Anhedonia</li><li>\u27a4 lack of mood reactivity</li><li>\u27a4 A distinct quality of intensely depressed mood , often referred to as a state of despondency or despair , also called as empty mood . The patients feels miserable.</li><li>\u27a4 distinct quality</li><li>\u27a4 intensely depressed mood</li><li>\u27a4 state of despondency or despair</li><li>\u27a4 empty mood</li><li>\u27a4 Depression is worse in the morning</li><li>\u27a4 Excessive guilt.</li><li>\u27a4 These patients have a higher suicide risk .</li><li>\u27a4 patients have a higher suicide risk</li><li>\u27a4 Ref : Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 380-382.</li><li>\u27a4 :</li><li>\u27a4 Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 380-382.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f6ff6f94",
      "audio": ""
    },
    {
      "text": "A 30-year-old man visits his primary care physician, reporting new-onset dry mouth, constipation, and blurred vision. He mentions that he was recently prescribed amitriptyline for depression. Which receptor's antagonism by amitriptyline is most likely responsible for the side effects he's experiencing?",
      "options": [
        {
          "label": "A",
          "text": "Dopamine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Histamine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Muscarinic",
          "correct": true
        },
        {
          "label": "D",
          "text": "Norepinephrine",
          "correct": false
        }
      ],
      "correct_answer": "C. Muscarinic",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/03/12/screenshot-2024-03-12-113259.jpg"
      ],
      "explanation": "<p><strong>Ans. C) Muscarinic</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A: Dopamine: Dopamine receptor antagonism is more characteristic of antipsychotic medications and can lead to extrapyramidal side effects , but it is not typically associated with the symptoms the patient is experiencing.</li><li>\u2022 Option A: Dopamine:</li><li>\u2022 Dopamine receptor antagonism</li><li>\u2022 antipsychotic medications</li><li>\u2022 lead to extrapyramidal side effects</li><li>\u2022 Option B: Histamine: Histamine (H1) receptor antagonism can cause sedation and weight gain , which are also side effects of TCAs , but they are not responsible for the dry mouth, constipation, and blurred vision.</li><li>\u2022 Option B: Histamine:</li><li>\u2022 Histamine</li><li>\u2022 receptor antagonism</li><li>\u2022 sedation and weight gain</li><li>\u2022 also side effects of TCAs</li><li>\u2022 Option D: Norepinephrine: Norepinephrine reuptake inhibition is a mechanism of action of TCAs in treating depression but does not directly cause the anticholinergic side effects mentioned.</li><li>\u2022 Option D: Norepinephrine:</li><li>\u2022 Norepinephrine reuptake inhibition</li><li>\u2022 mechanism of action of TCAs in treating depression</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Ref : Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 642 .</li><li>\u27a4 :</li><li>\u27a4 Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 642</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a32726e6",
      "audio": ""
    },
    {
      "text": "A 24-year-old female is brought to the emergency department by her roommate, who found her drowsy next to an empty pill bottle. The patient is lethargic with a blood pressure of 90/50 mmHg. On examination, her pupils are dilated, and her mouth is dry. An ECG shows a wide QRS complex with a rightward axis. The empty pill bottle previously contained an older type of antidepressant medication. What is the most appropriate immediate intervention?",
      "options": [
        {
          "label": "A",
          "text": "Hemodialysis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Flumazenil",
          "correct": false
        },
        {
          "label": "C",
          "text": "Sodium bicarbonate",
          "correct": true
        },
        {
          "label": "D",
          "text": "Fomepizole",
          "correct": false
        }
      ],
      "correct_answer": "C. Sodium bicarbonate",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/03/12/screenshot-2024-03-12-114329.jpg"
      ],
      "explanation": "<p><strong>Ans. C) Sodium bicarbonate</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A: Hemodialysis is not effective in removing TCAs from the body due to their high protein binding and large volume of distribution.</li><li>\u2022 Option A:</li><li>\u2022 Hemodialysis is not effective in removing TCAs</li><li>\u2022 Option B: Flumazenil is an antagonist used to reverse the effects of benzodiazepines , not TCAs.</li><li>\u2022 Option B:</li><li>\u2022 Flumazenil is an antagonist used to reverse the effects of benzodiazepines</li><li>\u2022 Option D: Fomepizole is an antidote for toxic alcohol ingestion (such as methanol and ethylene glycol), not for TCA overdose.</li><li>\u2022 Option D:</li><li>\u2022 Fomepizole is an antidote for toxic alcohol ingestion</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Ref : Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 644 .</li><li>\u27a4 :</li><li>\u27a4 Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 644</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "bee3bbce",
      "audio": ""
    },
    {
      "text": "Tricyclic antidepressants are contraindicated in:",
      "options": [
        {
          "label": "A",
          "text": "Glaucoma",
          "correct": true
        },
        {
          "label": "B",
          "text": "Brain tumor",
          "correct": false
        },
        {
          "label": "C",
          "text": "Bronchial asthma",
          "correct": false
        },
        {
          "label": "D",
          "text": "Hypertension",
          "correct": false
        }
      ],
      "correct_answer": "A. Glaucoma",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Glaucoma</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B: Brain tumor: While not an absolute contraindication , TCAs should be used cautiously in patients with a brain tumor , particularly if there is increased intracranial pressure, as the anticholinergic effects can potentially worsen certain symptoms.</li><li>\u2022 Option B: Brain tumor:</li><li>\u2022 not an absolute contraindication</li><li>\u2022 TCAs should be used cautiously in patients with a brain tumor</li><li>\u2022 Option C: Bronchial asthma: TCAs might not be contraindicated in asthma , but caution is advised due to their anticholinergic effects, which can potentially affect bronchial secretions and muscle tone.</li><li>\u2022 Option C: Bronchial asthma:</li><li>\u2022 TCAs might not be contraindicated in asthma</li><li>\u2022 Option D: Hypertension: TCAs can be used in patients with hypertension , but with caution, as they can cause orthostatic hypotension, so careful monitoring would be necessary.</li><li>\u2022 Option D: Hypertension:</li><li>\u2022 TCAs can be used in patients with hypertension</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Tricyclic antidepressants (TCAs) possess anticholinergic properties , which can lead to a variety of side effects . One of the primary concerns with the anticholinergic action of TCAs is the potential to precipitate an acute narrow-angle glaucoma attack in susceptible individuals. Hence, TCAs are contraindicated in patients with narrow-angle glaucoma.</li><li>\u27a4 Tricyclic antidepressants</li><li>\u27a4 possess anticholinergic properties</li><li>\u27a4 lead to a variety of side effects</li><li>\u27a4 primary concerns with the anticholinergic action of TCAs</li><li>\u27a4 potential to precipitate an acute narrow-angle glaucoma attack</li><li>\u27a4 Ref : Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 642 .</li><li>\u27a4 Ref :</li><li>\u27a4 Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 642</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f3f30e41",
      "audio": ""
    },
    {
      "text": "A 42-year-old male with a history of severe depression is admitted to the psychiatric unit for treatment. He has been started on Amitriptyline and, after 4 weeks of therapy, shows significant improvement in his depressive symptoms. He no longer reports feelings of hopelessness and has started to engage more with his family and hospital staff. As his physician, you are preparing for his discharge and considering the potential risks associated with his medication at this stage of treatment. At the time of his discharge, which of the following is the most important concern with Amitriptyline therapy in this patient?",
      "options": [
        {
          "label": "A",
          "text": "Suicidal tendencies with overdose of Amitriptyline",
          "correct": true
        },
        {
          "label": "B",
          "text": "Therapeutic drug monitoring of Amitriptyline",
          "correct": false
        },
        {
          "label": "C",
          "text": "ECG monitoring for arrhythmias",
          "correct": false
        },
        {
          "label": "D",
          "text": "Prescribing modafinil to counteract sedation due to Amitriptyline",
          "correct": false
        }
      ],
      "correct_answer": "A. Suicidal tendencies with overdose of Amitriptyline",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Suicidal tendencies with overdose of Amitriptyline</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Therapeutic drug monitoring of Amitriptyline: While important in the long-term management to ensure therapeutic levels and prevent toxicity , it is not typically the most critical concern at discharge.</li><li>\u2022 Option B. Therapeutic drug monitoring of Amitriptyline:</li><li>\u2022 long-term management to ensure therapeutic levels</li><li>\u2022 prevent toxicity</li><li>\u2022 Option C. ECG monitoring for arrhythmias: Amitriptyline can cause cardiac arrhythmias, particularly in overdose or in patients with pre-existing heart conditions . Regular ECG monitoring is advisable but secondary to the concern of suicidal tendencies in the immediate discharge period.</li><li>\u2022 Option C. ECG monitoring for arrhythmias: Amitriptyline</li><li>\u2022 cardiac arrhythmias,</li><li>\u2022 overdose or in patients with pre-existing heart conditions</li><li>\u2022 Option D. Prescribing modafinil to counteract sedation due to Amitriptyline: While Amitriptyline can cause sedation, addressing the risk of suicidal ideation and overdose is a more pressing concern. Modafinil is not commonly prescribed solely to counteract sedation from antidepressants and has its own set of considerations and potential side effects.</li><li>\u2022 Option D. Prescribing modafinil to counteract sedation due to Amitriptyline:</li><li>\u2022 Amitriptyline can cause sedation,</li><li>\u2022 addressing the risk of suicidal ideation</li><li>\u2022 overdose is a more pressing concern.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In certain cases, a person with depression might die by suicide while their symptoms show signs of improvement after beginning antidepressant treatment. This is referred to as paradoxical suicide , as it occurs when symptoms have already started to improve . The hypothesis is that a depressed individual may not have the energy to act on suicidal thoughts initially; however, as their condition begins to improve, their energy levels increase before their suicidal thoughts subside.</li><li>\u27a4 a person with depression might die by suicide while their symptoms show signs of improvement</li><li>\u27a4 beginning antidepressant treatment.</li><li>\u27a4 referred</li><li>\u27a4 paradoxical suicide</li><li>\u27a4 occurs when symptoms have already started to improve</li><li>\u27a4 Ref: Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 380.</li><li>\u27a4 Ref:</li><li>\u27a4 Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 380.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "fad473f0",
      "audio": ""
    },
    {
      "text": "A 45-year-old woman presents to the emergency department with tremors, hyperreflexia, and diaphoresis. On examination, she has dilated pupils and her temperature is 39\u00b0C (102.2\u00b0F). Her medical history reveals she started on an SSRI for depression two weeks ago. Additionally, she mentions taking another medication, the name of which she could not recall. Given her presentation and concurrent medications, which agents, when combined with SSRIs, can elevate serotonin levels and potentially result in the observed clinical picture?",
      "options": [
        {
          "label": "A",
          "text": "Lithium",
          "correct": false
        },
        {
          "label": "B",
          "text": "MAOIs",
          "correct": false
        },
        {
          "label": "C",
          "text": "Sumatriptan",
          "correct": false
        },
        {
          "label": "D",
          "text": "All of the above",
          "correct": true
        }
      ],
      "correct_answer": "D. All of the above",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/03/12/screenshot-2024-03-12-115450.jpg"
      ],
      "explanation": "<p><strong>Ans. D) All of the above</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A: Lithium: While primarily used as a mood stabilizer in bipolar disorder , lithium can increase serotonin levels and, when combined with SSRIs , may contribute to serotonin syndrome .</li><li>\u2022 Option A: Lithium:</li><li>\u2022 primarily used as a mood stabilizer in bipolar disorder</li><li>\u2022 increase serotonin levels and, when combined with SSRIs</li><li>\u2022 serotonin syndrome</li><li>\u2022 Option B: MAOIs (Monoamine Oxidase Inhibitors): These antidepressants inhibit the enzyme monoamine oxidase , which breaks down serotonin . Combining MAOIs with SSRIs can lead to excessive serotonin accumulation and a high risk of serotonin syndrome.</li><li>\u2022 Option B: MAOIs (Monoamine Oxidase Inhibitors):</li><li>\u2022 antidepressants inhibit the enzyme monoamine oxidase</li><li>\u2022 breaks down serotonin</li><li>\u2022 Option C: Sumatriptan: This is a medication used for migraine treatment and is a serotonin receptor agonist. When combined with SSRIs, there is an increased risk of serotonin syndrome due to additive effects on serotonin levels.</li><li>\u2022 Option C: Sumatriptan:</li><li>\u2022 medication used for migraine treatment and is a serotonin receptor agonist.</li><li>\u2022 The combination of any of these agents with an SSRI can increase the risk of developing serotonin syndrome.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Concurrent administration of an SSRI with MAO inhibitor, L-tryptophan or lithium can raise plasma serotonin concentration , resulting in serotonin syndrome. It is a potentially life-threatening condition.</li><li>\u27a4 Concurrent administration of an SSRI</li><li>\u27a4 MAO inhibitor, L-tryptophan or lithium</li><li>\u27a4 raise plasma serotonin concentration</li><li>\u27a4 serotonin syndrome.</li><li>\u27a4 Management includes discontinuation of serotonergic agents (most crucial), supportive care and cyproheptadine.</li><li>\u27a4 Management includes discontinuation of serotonergic agents</li><li>\u27a4 Ref : The Maudsley Prescribing Guidelines in Psychiatry, 14th edition, Page No 337.</li><li>\u27a4 :</li><li>\u27a4 The Maudsley Prescribing Guidelines in Psychiatry, 14th edition, Page No 337.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "382c9444",
      "audio": ""
    },
    {
      "text": "A 35-year-old man comes to his primary care physician complaining of difficulties in his intimate relationship. He mentions that ever since he started a medication for his depressive symptoms three months ago, he has experienced a decreased libido and difficulty maintaining an erection. He denies any cardiovascular issues, and his physical examination is unremarkable. Which of the following medications is most likely responsible for his symptoms?",
      "options": [
        {
          "label": "A",
          "text": "Fluoxetine",
          "correct": true
        },
        {
          "label": "B",
          "text": "Mirtazapine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Bupropion",
          "correct": false
        },
        {
          "label": "D",
          "text": "None of the above",
          "correct": false
        }
      ],
      "correct_answer": "A. Fluoxetine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Fluoxetine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B: Mirtazapine: This works as a noradrenergic and specific serotonergic antidepressant (NaSSA), is generally less likely to cause sexual dysfunction compared to SSRIs and SNRIs.</li><li>\u2022 Option B: Mirtazapine:</li><li>\u2022 works as a noradrenergic and specific serotonergic antidepressant</li><li>\u2022 Option C: Bupropion: This is a norepinephrine-dopamine reuptake inhibitor (NDRI) and is actually associated with a lower risk of sexual side effects . In some cases, it is used to counteract sexual dysfunction caused by SSRIs and SNRIs.</li><li>\u2022 Option C: Bupropion:</li><li>\u2022 norepinephrine-dopamine reuptake inhibitor</li><li>\u2022 actually associated with a lower risk of sexual side effects</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Sexual dysfunction , including decreased libido and difficulty maintaining an erection , is a common side effect of SSRIs like fluoxetine. These medications increase serotonin levels , which can adversely affect sexual desire and performance . In contrast, antidepressants like mirtazapine and bupropion are less likely to cause sexual dysfunction and may even be used to mitigate these side effects when they occur with other antidepressants.</li><li>\u27a4 Sexual dysfunction</li><li>\u27a4 decreased libido and difficulty maintaining an erection</li><li>\u27a4 common side effect of SSRIs like fluoxetine.</li><li>\u27a4 increase serotonin levels</li><li>\u27a4 adversely affect sexual desire and performance</li><li>\u27a4 Side effects of SSRIs include:</li><li>\u27a4 Side effects of SSRIs include:</li><li>\u27a4 Most common: Nausea The most common long-term side effects: Sexual dysfunction including delayed orgasm, poor erection, and low libido . CNS side effects- Paradoxical anxiety, sedation, vivid dreams, sweating, seizures, EPSE , etc. QTc prolongation Weight gain</li><li>\u27a4 Most common: Nausea</li><li>\u27a4 Nausea</li><li>\u27a4 The most common long-term side effects: Sexual dysfunction including delayed orgasm, poor erection, and low libido .</li><li>\u27a4 Sexual dysfunction including delayed orgasm, poor erection, and low libido</li><li>\u27a4 CNS side effects- Paradoxical anxiety, sedation, vivid dreams, sweating, seizures, EPSE , etc.</li><li>\u27a4 Paradoxical anxiety, sedation, vivid dreams, sweating, seizures, EPSE</li><li>\u27a4 QTc prolongation</li><li>\u27a4 Weight gain</li><li>\u27a4 Ref : Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 628-630.</li><li>\u27a4 Ref :</li><li>\u27a4 Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 628-630.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d4696e8d",
      "audio": ""
    },
    {
      "text": "A patient has been prescribed escitalopram for the treatment of anxiety. During a follow-up visit, the patient inquires about potential side effects of the medication. Which of the following is not a common side effect of escitalopram?",
      "options": [
        {
          "label": "A",
          "text": "Nausea",
          "correct": false
        },
        {
          "label": "B",
          "text": "Vivid dreams",
          "correct": false
        },
        {
          "label": "C",
          "text": "Anorgasmia",
          "correct": false
        },
        {
          "label": "D",
          "text": "Sialorrhea",
          "correct": true
        }
      ],
      "correct_answer": "D. Sialorrhea",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Sialorrhea</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Nausea is a well-known and common side effect of escitalopram , especially when the medication is first initiated or when the dose is increased.</li><li>\u2022 Option A.</li><li>\u2022 Nausea is a well-known</li><li>\u2022 common side effect of escitalopram</li><li>\u2022 Option B. Vivid dreams or nightmares can occur with the use of escitalopram, though they are not as common as other side effects.</li><li>\u2022 Option B.</li><li>\u2022 Vivid dreams or nightmares</li><li>\u2022 use of escitalopram,</li><li>\u2022 Option C. Anorgasmia is a known sexual side effect of SSRIs , including escitalopram.</li><li>\u2022 Option C.</li><li>\u2022 Anorgasmia is a known sexual side effect of SSRIs</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Sialorrhea (excessive salivation) is not a common side effect of escitalopram. Sialorrhea is a common side effect of clozapine.</li><li>\u27a4 Sialorrhea</li><li>\u27a4 not a common side effect of escitalopram.</li><li>\u27a4 Ref : Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 628-630.</li><li>\u27a4 Ref : Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 628-630.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2985dfe8",
      "audio": ""
    },
    {
      "text": "A patient with depression is being evaluated for pharmacological treatment options. The healthcare provider aims to choose a medication and dose that is within the accepted therapeutic range for treating depression. Which of the following drug and dose combinations has been correctly matched with its adequate antidepressant dose?",
      "options": [
        {
          "label": "A",
          "text": "Fluoxetine 10 mg",
          "correct": false
        },
        {
          "label": "B",
          "text": "Fluoxetine 20 mg",
          "correct": true
        },
        {
          "label": "C",
          "text": "Amitriptyline 25 mg",
          "correct": false
        },
        {
          "label": "D",
          "text": "Amitriptyline 10 mg",
          "correct": false
        }
      ],
      "correct_answer": "B. Fluoxetine 20 mg",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Fluoxetine 20 mg</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A: Fluoxetine 10 mg: While 10 mg can be a starting dose for some patients , especially those who may be sensitive to medication side effects , it is generally on the lower end of the therapeutic range for depression. The more standard starting dose is 20 mg.</li><li>\u2022 Option A: Fluoxetine 10 mg:</li><li>\u2022 While 10 mg can be a starting dose for some patients</li><li>\u2022 sensitive to medication side effects</li><li>\u2022 Option C: Amitriptyline 25 mg: Its therapeutic dose for depression generally starts at around 75 mg per day, which can be increased as needed and tolerated . A dose of 25 mg is considered subtherapeutic for depression, although it may be used for other indications like chronic pain or migraines.</li><li>\u2022 Option C: Amitriptyline 25 mg:</li><li>\u2022 starts at around 75 mg per day, which can be increased as needed and tolerated</li><li>\u2022 Option D: Amitriptyline 10 mg: This dose is also subtherapeutic for depression and is more likely to be used for other indications like chronic pain or migraines.</li><li>\u2022 Option D: Amitriptyline 10 mg:</li><li>\u2022 dose is also subtherapeutic for depression</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The typical starting dose of fluoxetine for the treatment of depression is 20 mg once daily , which is within the accepted therapeutic range . Lower doses of fluoxetine and lower doses of amitriptyline (such as 10 mg or 25 mg) are generally considered subtherapeutic for depression .</li><li>\u27a4 starting dose of fluoxetine for the treatment of depression is 20 mg once daily</li><li>\u27a4 within the accepted therapeutic range</li><li>\u27a4 Lower doses of fluoxetine</li><li>\u27a4 lower doses of amitriptyline</li><li>\u27a4 subtherapeutic for depression</li><li>\u27a4 Ref : Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 631.</li><li>\u27a4 :</li><li>\u27a4 Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 631.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7708f665",
      "audio": ""
    },
    {
      "text": "A 58-year-old man, recently hospitalized for a myocardial infarction, is seen in the cardiology clinic for follow-up. He reports feeling persistently sad, fatigued and has lost interest in activities he previously enjoyed. He admits to feeling \"worthless\" since his hospitalization. His cardiologist wants to address his mood symptoms and is considering the next steps in management. Which of the following statements regarding his condition and potential interventions is false?",
      "options": [
        {
          "label": "A",
          "text": "Depression can increase the risk of myocardial infarction.",
          "correct": false
        },
        {
          "label": "B",
          "text": "Experiencing a myocardial infarction can predispose to depression.",
          "correct": false
        },
        {
          "label": "C",
          "text": "SSRIs can be prescribed safely after a myocardial infarction to address depressive symptoms.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Only cognitive behavioral therapy should be recommended after myocardial infarction.",
          "correct": true
        }
      ],
      "correct_answer": "D. Only cognitive behavioral therapy should be recommended after myocardial infarction.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Only cognitive behavioral therapy should be recommended after myocardial infarction.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A: Depression can increase the risk of myocardial infarction: This is true . Depression is associated with an increased risk of coronary artery disease and subsequent MI.</li><li>\u2022 Option A: Depression can increase the risk of myocardial infarction:</li><li>\u2022 true</li><li>\u2022 Option B: Experiencing a myocardial infarction can predispose to depression: This is also true . The experience of having an MI can be psychologically traumatic, and the subsequent lifestyle changes and health concerns can contribute to the development of depression.</li><li>\u2022 Option B: Experiencing a myocardial infarction can predispose to depression:</li><li>\u2022 true</li><li>\u2022 Option C: SSRIs can be prescribed safely after a myocardial infarction to address depressive symptoms: This is true . SSRIs are generally considered safe in patients with heart disease and can be used to treat depression following an MI. They are preferred over other antidepressant classes like tricyclic antidepressants, which can have adverse cardiac effects.</li><li>\u2022 Option C: SSRIs can be prescribed safely after a myocardial infarction to address depressive symptoms:</li><li>\u2022 true</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Depression is common after a myocardial infarction and can affect recovery and outcomes . Both pharmacological (e.g., SSRIs) and non-pharmacological (e.g., CBT) interventions can be effective in treating post-MI depression.</li><li>\u27a4 Depression is common after a myocardial infarction</li><li>\u27a4 affect recovery and outcomes</li><li>\u27a4 pharmacological</li><li>\u27a4 non-pharmacological</li><li>\u27a4 interventions can be effective in treating post-MI depression.</li><li>\u27a4 Ref : T he Maudsley Prescribing Guidelines in Psychiatry, 14th edition, Page No 386.</li><li>\u27a4 Ref :</li><li>\u27a4 T he Maudsley Prescribing Guidelines in Psychiatry, 14th edition, Page No 386.</li><li>\u27a4 T</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "fdb2bc33",
      "audio": ""
    },
    {
      "text": "A 45-year-old woman, who has been on an antidepressant for the past year, is planning to discontinue her medication due to perceived improvement in her mood. She has heard stories about people experiencing unpleasant symptoms when stopping their antidepressants and is concerned about experiencing the same. Which of the following medications, if she was taking, would be the least likely to result in a discontinuation reaction?",
      "options": [
        {
          "label": "A",
          "text": "Venlafaxine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Fluoxetine",
          "correct": true
        },
        {
          "label": "C",
          "text": "Paroxetine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Citalopram",
          "correct": false
        }
      ],
      "correct_answer": "B. Fluoxetine",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/03/12/screenshot-2024-03-12-120654.jpg"
      ],
      "explanation": "<p><strong>Ans. B) Fluoxetine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A: Venlafaxine: This is an SNRI (serotonin-norepinephrine reuptake inhibitor) known for its potential to cause significant discontinuation syndrome , especially at higher doses, due to its short half-life.</li><li>\u2022 Option A: Venlafaxine:</li><li>\u2022 This is an SNRI</li><li>\u2022 potential to cause significant discontinuation syndrome</li><li>\u2022 Option C: Paroxetine: This SSRI has a short half-life and is also known for causing discontinuation symptoms.</li><li>\u2022 Option C: Paroxetine:</li><li>\u2022 SSRI has a short half-life</li><li>\u2022 known for causing discontinuation symptoms.</li><li>\u2022 Option D: Citalopram: While it has a longer half-life than venlafaxine or paroxetine , it is still more likely to produce discontinuation symptoms than fluoxetine.</li><li>\u2022 Option D: Citalopram:</li><li>\u2022 longer half-life than venlafaxine or paroxetine</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Discontinuation syndrome (often incorrectly referred to as \"withdrawal\") are symptoms that can occur when the dose of antidepressants is reduced or stopped abruptly . All antidepressants can cause discontinuation syndrome . Venlafaxine is most commonly associated with discontinuation syndrome . Short acting SSRIs such as paroxetine and fluvoxamine are also commonly associated with discontinuation syndrome. Fluoxetine, which is the long acting SSRI, is least likely to be associated with discontinuation syndrome. Therefore, the likelihood of experiencing discontinuation reactions can vary depending on the half-life of the drug; those with shorter half-lives tend to produce these reactions more frequently.</li><li>\u27a4 Discontinuation syndrome</li><li>\u27a4 symptoms that can occur when the dose of antidepressants is reduced or stopped abruptly</li><li>\u27a4 antidepressants</li><li>\u27a4 discontinuation syndrome</li><li>\u27a4 Venlafaxine is most commonly associated with discontinuation syndrome</li><li>\u27a4 Ref : The Maudsley Prescribing Guidelines in Psychiatry, 14th edition, Page No 343-346.</li><li>\u27a4 Ref : The Maudsley Prescribing Guidelines in Psychiatry, 14th edition, Page No 343-346.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1c7f4342",
      "audio": ""
    },
    {
      "text": "A 54-year-old woman with a history of treatment-resistant depression is under consideration for additional therapies to augment her current antidepressant regimen. Her psychiatrist is considering adding a hormone to her treatment plan to potentially boost the efficacy of her current medication. Which of the following hormones is most commonly used as an adjunct in the treatment of depression?",
      "options": [
        {
          "label": "A",
          "text": "Cortisol",
          "correct": false
        },
        {
          "label": "B",
          "text": "Levothyroxine",
          "correct": true
        },
        {
          "label": "C",
          "text": "ACTH",
          "correct": false
        },
        {
          "label": "D",
          "text": "Progesterone",
          "correct": false
        }
      ],
      "correct_answer": "B. Levothyroxine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Levothyroxine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A: Cortisol: Cortisol is a stress hormone produced by the adrenal glands . Elevated levels of cortisol are often associated with stress and may be counterproductive in the treatment of depression.</li><li>\u2022 Option A: Cortisol:</li><li>\u2022 stress hormone produced by the adrenal glands</li><li>\u2022 Option C: ACTH (Adrenocorticotropic hormone): ACTH stimulates the release of cortisol from the adrenal glands and is not used as a treatment for depression.</li><li>\u2022 Option C: ACTH (Adrenocorticotropic hormone):</li><li>\u2022 stimulates the release of cortisol from the adrenal glands</li><li>\u2022 Option D: Progesterone: Progesterone is a sex hormone that plays a role in the menstrual cycle and pregnancy . It is not commonly used as an adjunct in the treatment of depression.</li><li>\u2022 Option D: Progesterone:</li><li>\u2022 sex hormone that plays a role in the menstrual cycle and pregnancy</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Levothyroxine can be used as an adjunct therapy in the treatment of depression , particularly for patients with treatment-resistant depression . It can be effective even in patients without overt hypothyroidism.</li><li>\u27a4 Levothyroxine can be used as an adjunct therapy</li><li>\u27a4 treatment of depression</li><li>\u27a4 patients with treatment-resistant depression</li><li>\u27a4 effective even in patients without overt hypothyroidism.</li><li>\u27a4 Ref : The Maudsley Prescribing Guidelines in Psychiatry, 14th edition, Page No 321.</li><li>\u27a4 Ref :</li><li>\u27a4 The Maudsley Prescribing Guidelines in Psychiatry, 14th edition, Page No 321.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b1df2f38",
      "audio": ""
    },
    {
      "text": "A 68-year-old man presents to the outpatient clinic three months after suffering from a left-sided hemiplegic stroke. He reports persistent feelings of sadness, hopelessness, and a lack of interest in activities he once enjoyed. His family notes that he's become more withdrawn and less communicative since the stroke. He has a history of mild hypertension, which is well-controlled with medication. The psychiatrist considers pharmacological intervention for his depressive symptoms. Which of the following medications would be the most appropriate choice for his condition?",
      "options": [
        {
          "label": "A",
          "text": "Buspirone",
          "correct": false
        },
        {
          "label": "B",
          "text": "SSRI",
          "correct": true
        },
        {
          "label": "C",
          "text": "Nootropic drugs",
          "correct": false
        },
        {
          "label": "D",
          "text": "Amitriptyline",
          "correct": false
        }
      ],
      "correct_answer": "B. SSRI",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) SSRI</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A: Buspirone: It's an anxiolytic that's mainly used for generalized anxiety disorder and is not a first-line treatment for depression.</li><li>\u2022 Option A: Buspirone:</li><li>\u2022 anxiolytic</li><li>\u2022 mainly used for generalized anxiety disorder</li><li>\u2022 Option C: Nootropic drugs: These are cognitive enhancers that are not typically used as primary treatments for depression.</li><li>\u2022 Option C: Nootropic drugs:</li><li>\u2022 cognitive enhancers that are not typically used as primary treatments for depression.</li><li>\u2022 Option D: Amitriptyline: It's a tricyclic antidepressant. While effective for depression, it has a less favorable side effect profile compared to SSRIs , especially in elderly patients . It can cause anticholinergic effects, orthostatic hypotension, and can be cardiotoxic. Given the patient's age and stroke history, an SSRI would be a safer choice.</li><li>\u2022 Option D: Amitriptyline:</li><li>\u2022 tricyclic antidepressant.</li><li>\u2022 less favorable side effect profile compared to SSRIs</li><li>\u2022 elderly patients</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 SSRIs are preferred for post-stroke depression , especially in those with hypertension.</li><li>\u27a4 SSRIs</li><li>\u27a4 post-stroke depression</li><li>\u27a4 hypertension.</li><li>\u27a4 Ref : The Maudsley Prescribing Guidelines in Psychiatry, 14th edition, Page No 362 .</li><li>\u27a4 :</li><li>\u27a4 The Maudsley Prescribing Guidelines in Psychiatry, 14th edition, Page No 362</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "07a08a8d",
      "audio": ""
    },
    {
      "text": "During a weekly teaching session at the psychiatric residency program, Dr. Suresh Kumar presents a case of a 35-year-old male patient who recently began treatment for smoking cessation. The patient also has a history of depressive episodes but dislikes the sexual side effects he previously experienced with another antidepressant. Dr. Kumar prescribed bupropion not only for its efficacy in smoking cessation but also for its potential antidepressant effects without the sexual side effects commonly seen with some other classes of antidepressants. He then posed a question to the residents: \"Considering its unique profile, what best describes the primary mechanism of action of bupropion that differentiates it from many other antidepressants?\"",
      "options": [
        {
          "label": "A",
          "text": "Potentiation of serotonin neurotransmission.",
          "correct": false
        },
        {
          "label": "B",
          "text": "Inhibition of monoamine oxidase enzymes.",
          "correct": false
        },
        {
          "label": "C",
          "text": "Blockade of norepinephrine and dopamine reuptake.",
          "correct": true
        },
        {
          "label": "D",
          "text": "Enhancement of GABAergic activity.",
          "correct": false
        }
      ],
      "correct_answer": "C. Blockade of norepinephrine and dopamine reuptake.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Blockade of norepinephrine and dopamine reuptake.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A: Potentiation of serotonin neurotransmission: This is the primary mechanism of SSRIs and some other classes of antidepressants , but not bupropion. Bupropion does not have significant activity on serotonin receptors.</li><li>\u2022 Option A: Potentiation of serotonin neurotransmission:</li><li>\u2022 primary mechanism of SSRIs and some other classes of antidepressants</li><li>\u2022 Option B: Inhibition of monoamine oxidase enzymes: MAO inhibitors act by inhibiting the enzyme monoamine oxidase , thus preventing the breakdown of monoamine neurotransmitters and thereby increasing their availability. Bupropion is not an MAOI.</li><li>\u2022 Option B: Inhibition of monoamine oxidase enzymes:</li><li>\u2022 MAO inhibitors</li><li>\u2022 inhibiting the enzyme monoamine oxidase</li><li>\u2022 preventing the breakdown of monoamine neurotransmitters</li><li>\u2022 Option D: Enhancement of GABAergic activity: This is a mechanism associated with benzodiazepines and certain antiepileptic medications , not with bupropion.</li><li>\u2022 Option D: Enhancement of GABAergic activity:</li><li>\u2022 mechanism associated with benzodiazepines</li><li>\u2022 certain antiepileptic medications</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Bupropion belongs to a class called NDRI (norepinephrine dopamine reuptake inhibitors). The mechanism of action is inhibition of reuptake of both norepinephrine and dopamine . The advantage of bupropion is a good side effect profile with low risk of sexual side effects, weight gain or sedation. The common side effects are insomnia, tremors, restlessness and nausea. A particular worrisome side effect is seizures (usually seen at higher dosages). Bupropion is also used for smoking cessation.</li><li>\u2022 Bupropion belongs to a class called NDRI</li><li>\u2022 mechanism of action is inhibition of reuptake of both norepinephrine and dopamine</li><li>\u2022 advantage of bupropion is a good side effect profile</li><li>\u2022 low risk of sexual side effects, weight gain or sedation.</li><li>\u2022 Ref : Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 635-637.</li><li>\u2022 :</li><li>\u2022 Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 635-637.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "83baad3c",
      "audio": ""
    },
    {
      "text": "A 32-year-old man presents to the emergency department with a painful erection lasting for the past 5 hours. He denies any recent trauma, use of recreational drugs, or history of sickle cell disease. Upon further questioning, he mentions that he recently started a new medication for his depression and insomnia. His past medical history is unremarkable. On examination, the patient appears distressed. There is a fully turgid, painful penis without any signs of trauma. Urinalysis is within normal limits. Which of the following medications is most likely responsible for this patient's presentation?",
      "options": [
        {
          "label": "A",
          "text": "Fluoxetine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Lithium",
          "correct": false
        },
        {
          "label": "C",
          "text": "Trazodone",
          "correct": true
        },
        {
          "label": "D",
          "text": "Lamotrigine",
          "correct": false
        }
      ],
      "correct_answer": "C. Trazodone",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Trazodone</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A: Fluoxetine can cause sexual dysfunction but is not typically associated with priapism.</li><li>\u2022 Option A:</li><li>\u2022 Fluoxetine</li><li>\u2022 sexual dysfunction</li><li>\u2022 Option B: Lithium can cause several side effects , including tremor and thyroid dysfunction, but not priapism.</li><li>\u2022 Option B:</li><li>\u2022 Lithium</li><li>\u2022 several side effects</li><li>\u2022 Option D: Lamotrigine does not commonly cause priapism as a side effect.</li><li>\u2022 Option D:</li><li>\u2022 Lamotrigine</li><li>\u2022 not commonly cause priapism</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Trazodone and nefazodone are classified as SARI (serotonin antagonist and reuptake inhibitor). The mechanism of action is weak inhibition of serotonin reuptake and strong antagonism at 5 HT2A and 5 HT2C receptors . Trazodone can cause priapism as a side effect.</li><li>\u27a4 Trazodone and nefazodone are classified as SARI</li><li>\u27a4 mechanism of action is weak inhibition of serotonin reuptake</li><li>\u27a4 strong antagonism at 5 HT2A</li><li>\u27a4 5 HT2C receptors</li><li>\u27a4 Ref : Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 640.</li><li>\u27a4 Ref :</li><li>\u27a4 Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 640.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "deab2735",
      "audio": ""
    },
    {
      "text": "An 82-year-old retired army veteran is brought to the clinic by his concerned daughter. She recounts how, over the past 4 months, following the unexpected death of his only son, her father's demeanor has drastically changed. He often stares out the window, lost in thought, and breaks down in tears at the mention of his son's name. He has been expressing feelings of worthlessness and recently confided in her about considering \"ending it all.\" She's also noticed a drop in his appetite, with him unintentionally losing a significant amount of weight. His medical history is significant for benign prostatic hyperplasia, hypertension, type 2 diabetes managed with insulin, and a prior heart attack 5 years ago. Given his complex medical history, which medication would be best suited to address his depressive symptoms?",
      "options": [
        {
          "label": "A",
          "text": "Doxepin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Amitriptyline",
          "correct": false
        },
        {
          "label": "C",
          "text": "Sertraline",
          "correct": true
        },
        {
          "label": "D",
          "text": "Tranylcypromine",
          "correct": false
        }
      ],
      "correct_answer": "C. Sertraline",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Sertraline</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A: Doxepin and B) Amitriptyline are tricyclic antidepressants (TCAs). They are generally avoided in older patients due to their anticholinergic side effects (which can worsen benign prostatic hyperplasia and cause urinary retention, constipation, and dry mouth), orthostatic hypotension , and potential cardiac side effects (especially relevant in a patient with a history of heart attack).</li><li>\u2022 Option A:</li><li>\u2022 Doxepin</li><li>\u2022 Amitriptyline are tricyclic antidepressants</li><li>\u2022 They are generally avoided in older patients due to their anticholinergic side effects</li><li>\u2022 orthostatic hypotension</li><li>\u2022 cardiac side effects</li><li>\u2022 Option D: Tranylcypromine is a monoamine oxidase inhibitor (MAOI). MAOIs are typically used as a last resort due to their numerous dietary restrictions and potential for severe interactions with other medications , making them less suitable for elderly patients with multiple comorbidities and on multiple drugs.</li><li>\u2022 Option D:</li><li>\u2022 Tranylcypromine is a monoamine oxidase inhibitor</li><li>\u2022 MAOIs</li><li>\u2022 dietary restrictions and potential for severe interactions with other medications ,</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In elderly patients with depression, especially those with multiple comorbidities, SSRIs like sertraline are generally preferred due to their favorable side effect profile and safety in case of overdose . They are often the first line for treating depression in the elderly. Tricyclic antidepressants and MAOIs are usually avoided in the elderly due to their higher risk of side effects and interactions.</li><li>\u27a4 multiple comorbidities, SSRIs like sertraline are generally preferred due to their favorable side effect</li><li>\u27a4 safety in case of overdose</li><li>\u27a4 Ref : The Maudsley Prescribing Guidelines in Psychiatry, 14th edition, Page No 675.</li><li>\u27a4 :</li><li>\u27a4 The Maudsley Prescribing Guidelines in Psychiatry, 14th edition, Page No 675.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e58ec072",
      "audio": ""
    },
    {
      "text": "A 35-year-old woman with a history of recurrent major depressive disorder is being managed with medication in your clinic. She is a nutrition enthusiast and reads about an experimental tryptophan-free amino acid mixture that she decides to try. A week later, she reports a noticeable worsening of her depressive symptoms. Given the role of tryptophan in neurotransmitter synthesis, which of the following treatments she might be on is most likely responsible for the observed exacerbation of her symptoms upon tryptophan depletion?",
      "options": [
        {
          "label": "A",
          "text": "Selective serotonin reuptake inhibitors (SSRIs)",
          "correct": true
        },
        {
          "label": "B",
          "text": "Tricyclic antidepressants",
          "correct": false
        },
        {
          "label": "C",
          "text": "Reboxetine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Cognitive behavioral therapy",
          "correct": false
        }
      ],
      "correct_answer": "A. Selective serotonin reuptake inhibitors (SSRIs)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Selective serotonin reuptake inhibitors (SSRIs)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B: Tricyclic antidepressants: While TCAs also affect serotonin levels , they do so by a different mechanism compared to SSRIs and also impact other neurotransmitters like norepinephrine .</li><li>\u2022 Option B: Tricyclic antidepressants:</li><li>\u2022 TCAs also affect serotonin levels</li><li>\u2022 impact other neurotransmitters like norepinephrine</li><li>\u2022 Option C: Reboxetine: This is a norepinephrine reuptake inhibitor and its mechanism of action is primarily on the norepinephrine system , not serotonin.</li><li>\u2022 Option C: Reboxetine:</li><li>\u2022 norepinephrine reuptake inhibitor and its mechanism of action is primarily on the norepinephrine system</li><li>\u2022 Option D: Cognitive behavioral therapy: This is a psychotherapeutic approach and is not directly affected by biological changes related to tryptophan levels .</li><li>\u2022 Option D: Cognitive behavioral therapy:</li><li>\u2022 psychotherapeutic approach and is not directly affected by biological changes</li><li>\u2022 tryptophan levels</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Selective serotonin reuptake inhibitors (SSRIs) function by blocking the reuptake of serotonin in the synaptic cleft , increasing its availability in the synapse . When there's a depletion of tryptophan , and consequently serotonin, the therapeutic effect of SSRIs can be compromised, potentially exacerbating depressive symptoms.</li><li>\u27a4 Selective serotonin reuptake inhibitors</li><li>\u27a4 blocking the reuptake of serotonin in the synaptic cleft</li><li>\u27a4 increasing its availability in the synapse</li><li>\u27a4 depletion of tryptophan</li><li>\u27a4 consequently serotonin,</li><li>\u27a4 Ref : Stahl\u2019s Neuroscientific basis and practical applications, 5th edition, Page No 289.</li><li>\u27a4 :</li><li>\u27a4 Stahl\u2019s Neuroscientific basis and practical applications, 5th edition, Page No 289.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "886f720f",
      "audio": ""
    },
    {
      "text": "A 35-year-old female presents to the clinic with a two-week history of persistent sadness, loss of interest in activities, significant weight loss, and recurrent thoughts of death. She has no past medical history, and her physical examination is unremarkable. Given her presentation of acute severe depression, the clinician aims to initiate pharmacotherapy with a medication that has a favorable side-effect profile. Which of the following drugs is considered the drug of choice for acute severe depression with the least side effects?",
      "options": [
        {
          "label": "A",
          "text": "MAO inhibitors",
          "correct": false
        },
        {
          "label": "B",
          "text": "TCAs",
          "correct": false
        },
        {
          "label": "C",
          "text": "Serotonin modulators",
          "correct": false
        },
        {
          "label": "D",
          "text": "Serotonin-noradrenaline reuptake inhibitor (SNRI)",
          "correct": true
        }
      ],
      "correct_answer": "D. Serotonin-noradrenaline reuptake inhibitor (SNRI)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Serotonin-noradrenaline reuptake inhibitor (SNRI)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A: Monoamine oxidase (MAO) inhibitors are effective for depression but are associated with significant side effects and dietary restrictions due to the risk of hypertensive crisis with the ingestion of tyramine-rich foods.</li><li>\u2022 Option A:</li><li>\u2022 Monoamine oxidase</li><li>\u2022 inhibitors</li><li>\u2022 depression but are associated with significant side effects</li><li>\u2022 dietary restrictions due to the risk of hypertensive crisis</li><li>\u2022 Option B: Tricyclic antidepressants (TCAs) are also effective but are associated with anticholinergic side effects, sedation, and cardiotoxicity , especially in overdose, making them less favorable, particularly in patients with suicidal ideation.</li><li>\u2022 Option B:</li><li>\u2022 Tricyclic antidepressants</li><li>\u2022 effective but are associated with anticholinergic side effects, sedation, and cardiotoxicity</li><li>\u2022 Option C: Serotonin modulators , such as trazodone, can be useful but are not typically considered first-line for severe depression. They can also have side effects such as sedation and, rarely, priapism.</li><li>\u2022 Option C:</li><li>\u2022 Serotonin modulators</li><li>\u2022 trazodone,</li><li>\u2022 useful but are not typically considered first-line for severe depression.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Most of the studies have found that all the classes of antidepressants have same efficacy . However some studies have found that SNRIs to be more effective than SSRIs. This is attributed to the action of SNRIs on both norepinephrine as well as serotonin receptors. TCAs too act on multiple receptors but are associated with serious side effects.</li><li>\u27a4 classes of antidepressants have same efficacy</li><li>\u27a4 SNRIs to be more effective than SSRIs.</li><li>\u27a4 Ref : Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 632-633.</li><li>\u27a4 :</li><li>\u27a4 Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 632-633.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0354c00d",
      "audio": ""
    },
    {
      "text": "In the context of antidepressant use, the \"placebo effect\" is most strongly associated with which of the following psychiatric disorders?",
      "options": [
        {
          "label": "A",
          "text": "Mild depression",
          "correct": true
        },
        {
          "label": "B",
          "text": "OCD",
          "correct": false
        },
        {
          "label": "C",
          "text": "Specific phobias",
          "correct": false
        },
        {
          "label": "D",
          "text": "Generalized anxiety disorder",
          "correct": false
        }
      ],
      "correct_answer": "A. Mild depression",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Mild depression</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B: OCD typically has a lower placebo response rate . The chronic and often severe nature of OCD might contribute to this, as well as the specific and intense nature of the obsessions and compulsions associated with the disorder.</li><li>\u2022 Option B:</li><li>\u2022 OCD</li><li>\u2022 lower placebo response rate</li><li>\u2022 Option C: Specific phobias are usually treated with behavioral interventions like exposure therapy, not antidepressants . While placebo effects can occur in the treatment of phobias, they are not as strongly associated with placebo responses as mild depression.</li><li>\u2022 Option C:</li><li>\u2022 phobias are usually treated with behavioral interventions</li><li>\u2022 exposure therapy, not antidepressants</li><li>\u2022 Option D: Generalized anxiety disorder does have a placebo response , but not to the extent observed in mild depression . Antidepressants can be effective in treating GAD, but the placebo effect is something clinicians need to be aware of.</li><li>\u2022 Option D:</li><li>\u2022 Generalized anxiety disorder</li><li>\u2022 placebo response</li><li>\u2022 not to the extent observed in mild depression</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objectives:</li><li>\u27a4 Placebo effect is particularly pronounced in the treatment of mild depression with antidepressants.</li><li>\u27a4 Placebo effect</li><li>\u27a4 pronounced in the treatment of mild depression</li><li>\u27a4 antidepressants.</li><li>\u27a4 Ref : The Maudsley Prescribing Guidelines in Psychiatry, 14th edition, Page No 307.</li><li>\u27a4 Ref :</li><li>\u27a4 The Maudsley Prescribing Guidelines in Psychiatry, 14th edition, Page No 307.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c1c00574",
      "audio": ""
    },
    {
      "text": "A 56-year-old male with a history of depression is being treated with escitalopram. He was recently prescribed thiazide diuretics for newly diagnosed hypertension. He presents to the emergency department with acute onset confusion and disorientation. Laboratory workup is initiated to identify the cause of his symptoms. Considering his medication regimen and the potential side effects, what is the most likely cause of his confusion?",
      "options": [
        {
          "label": "A",
          "text": "Hyponatremia",
          "correct": true
        },
        {
          "label": "B",
          "text": "Hypokalemia",
          "correct": false
        },
        {
          "label": "C",
          "text": "Drug interaction",
          "correct": false
        },
        {
          "label": "D",
          "text": "Serotonin syndrome",
          "correct": false
        }
      ],
      "correct_answer": "A. Hyponatremia",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/03/12/picture1_G1pQphq.jpg"
      ],
      "explanation": "<p><strong>Ans. A) Hyponatremia</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B: Hypokalemia can cause confusion but is less likely in this context . Thiazide diuretics are more commonly associated with hypokalemia , but the patient's use of escitalopram points towards hyponatremia.</li><li>\u2022 Option B:</li><li>\u2022 Hypokalemia</li><li>\u2022 confusion but is less likely in this context</li><li>\u2022 Thiazide diuretics are more commonly associated with hypokalemia</li><li>\u2022 Option C: Drug interactions : While drug interactions are possible, the symptoms and context provided are more indicative of hyponatremia due to the combined effects of escitalopram and the thiazide diuretic.</li><li>\u2022 Option C:</li><li>\u2022 Drug interactions</li><li>\u2022 symptoms and context provided are more indicative of hyponatremia</li><li>\u2022 Option D: Serotonin syndrome is a potentially life-threatening condition resulting from an excess of serotonin . Symptoms include agitation, confusion, rapid heartbeat, and high blood pressure. While the patient is on escitalopram, there is no indication of serotonin syndrome in the vignette.</li><li>\u2022 Option D:</li><li>\u2022 Serotonin syndrome</li><li>\u2022 life-threatening condition resulting from an excess of serotonin</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 SSRIs can cause hyponatremia. The onset is usually within 30 days of starting treatment . The mechanism is SIADH. It can happen particularly in older adults, females and when used in combination with other medications like diuretics, NSAIDs, ACE inhibitors etc.</li><li>\u27a4 SSRIs can cause hyponatremia.</li><li>\u27a4 30 days of starting treatment</li><li>\u27a4 Management depends upon the serum sodium levels.</li><li>\u27a4 Ref : The Maudsley Prescribing Guidelines in Psychiatry, 14th edition, Page No 394-395.</li><li>\u27a4 Ref :</li><li>\u27a4 The Maudsley Prescribing Guidelines in Psychiatry, 14th edition, Page No 394-395.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "578987a6",
      "audio": ""
    },
    {
      "text": "Ms. R, a 37-year-old woman, is admitted to the inpatient psychiatric unit following her third suicide attempt in the past two years. The nursing staff reports that she often remains in bed for the majority of the day, rarely interacts with others, and has been frequently observed crying. A review of her medical records indicates a significant weight loss of 18 kg over the past two years. Given the acute severity and risk associated with her condition, you are considering various treatment options to address her immediate needs. Which of the following treatment modalities would be least appropriate as an initial intervention for Ms. R's current presentation?",
      "options": [
        {
          "label": "A",
          "text": "Brief psychodynamic therapy",
          "correct": true
        },
        {
          "label": "B",
          "text": "Cognitive behavioral therapy (CBT)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Electroconvulsive therapy (ECT)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Pharmacotherapy",
          "correct": false
        }
      ],
      "correct_answer": "A. Brief psychodynamic therapy",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Brief psychodynamic therapy</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B: Cognitive behavioral therapy (CBT): Effective for depression , it offers coping tools . However, its success hinges on active patient participation, which might be challenging in acute distress.</li><li>\u2022 Option B: Cognitive behavioral therapy (CBT):</li><li>\u2022 Effective for depression</li><li>\u2022 offers coping tools</li><li>\u2022 Option C: Electroconvulsive therapy (ECT): A potent intervention for severe depression , ECT can swiftly alleviate symptoms, especially in cases resistant to other treatments.</li><li>\u2022 Option C: Electroconvulsive therapy (ECT):</li><li>\u2022 potent intervention for severe depression</li><li>\u2022 Option D: Pharmacotherapy: Antidepressants can be commenced immediately , addressing the depression's neurochemical aspects . They may take time for full effect but can begin symptom relief sooner.</li><li>\u2022 Option D: Pharmacotherapy:</li><li>\u2022 Antidepressants</li><li>\u2022 commenced immediately</li><li>\u2022 addressing the depression's neurochemical aspects</li><li>\u2022 Considering the need for rapid intervention in Ms. R's case, brief psychodynamic therapy is the least appropriate initial option.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In cases of severe depression with acute suicidality or significant functional impairment , rapid and effective treatments like ECT or pharmacotherapy are usually prioritized over therapies that may have a slower onset of therapeutic effects.</li><li>\u27a4 severe depression with acute suicidality</li><li>\u27a4 significant functional impairment</li><li>\u27a4 rapid and effective treatments like ECT</li><li>\u27a4 pharmacotherapy</li><li>\u27a4 prioritized over therapies</li><li>\u27a4 Ref : Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 393.</li><li>\u27a4 :</li><li>\u27a4 Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 393.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e87f7e82",
      "audio": ""
    },
    {
      "text": "A 35-year-old female is undergoing therapy for recurrent depressive episodes. During the sessions, her psychiatrist focuses on identifying, challenging, and altering her negative thought patterns and beliefs. The therapist works with her to develop healthier ways of thinking and behaving. Based on this approach, which type of psychotherapy is the patient most likely receiving?",
      "options": [
        {
          "label": "A",
          "text": "Psychodynamic psychotherapy",
          "correct": false
        },
        {
          "label": "B",
          "text": "Cognitive behavioral therapy",
          "correct": true
        },
        {
          "label": "C",
          "text": "Behavioral therapy",
          "correct": false
        },
        {
          "label": "D",
          "text": "Interpersonal therapy",
          "correct": false
        }
      ],
      "correct_answer": "B. Cognitive behavioral therapy",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Cognitive behavioral therapy</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A: Psychodynamic Psychotherapy: This form of therapy focuses on exploring unconscious processes as they are manifested in a person's present behavior . The goals are to increase self-awareness and understanding of the influence of the past on present behavior.</li><li>\u2022 Option A: Psychodynamic Psychotherapy:</li><li>\u2022 form of therapy focuses on exploring unconscious processes</li><li>\u2022 manifested in a person's present behavior</li><li>\u2022 Option C: Behavioral Therapy: This approach focuses solely on changing maladaptive behaviors through techniques like conditioning, without the cognitive aspect of challenging and changing thought patterns.</li><li>\u2022 Option C: Behavioral Therapy:</li><li>\u2022 solely on changing maladaptive behaviors</li><li>\u2022 techniques like conditioning, without the cognitive aspect</li><li>\u2022 Option D: Interpersonal Therapy: This therapy focuses on interpersonal relationships and social functioning , aiming to improve communication patterns and how people relate to others.</li><li>\u2022 Option D: Interpersonal Therapy:</li><li>\u2022 therapy focuses on interpersonal relationships</li><li>\u2022 social functioning</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Cognitive Behavioral Therapy (CBT) is a form of psychotherapy that focuses on identifying and changing negative thought patterns and behaviors , with the aim of improving mental well-being.</li><li>\u27a4 Cognitive Behavioral Therapy</li><li>\u27a4 psychotherapy that focuses on identifying and changing negative thought patterns and behaviors</li><li>\u27a4 Ref : Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page 767-771.</li><li>\u27a4 Ref :</li><li>\u27a4 Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page 767-771.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1bebc306",
      "audio": ""
    },
    {
      "text": "A 46-year-old male has been diagnosed with recurrent depressive disorder and has had four major depressive episodes in the last five years. Each episode was characterized by feelings of worthlessness, loss of interest in daily activities, fatigue, and decreased appetite. On each occasion, the episodes resolved with treatment but he is keen to avoid further episodes in the future. His psychiatrist is discussing options for prophylactic therapy to reduce the risk of recurrence. Which of the following drugs is NOT commonly used in the prophylaxis of recurrent depressive episodes?",
      "options": [
        {
          "label": "A",
          "text": "Valproate",
          "correct": true
        },
        {
          "label": "B",
          "text": "Lithium",
          "correct": false
        },
        {
          "label": "C",
          "text": "Selective serotonin reuptake inhibitors",
          "correct": false
        },
        {
          "label": "D",
          "text": "TCAs",
          "correct": false
        }
      ],
      "correct_answer": "A. Valproate",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Valproate</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Lithium: Lithium is a well-established mood stabilizer that is often used for long-term prophylaxis in recurrent unipolar depressive disorder as well as in bipolar disorder.</li><li>\u2022 Option B. Lithium:</li><li>\u2022 well-established mood stabilizer</li><li>\u2022 used for long-term prophylaxis</li><li>\u2022 recurrent unipolar depressive disorder</li><li>\u2022 Option C. Selective serotonin reuptake inhibitors (SSRIs): SSRIs are commonly prescribed for long-term maintenance therapy to prevent recurrence of depressive episodes in patients with recurrent unipolar depression.</li><li>\u2022 Option C. Selective serotonin reuptake inhibitors (SSRIs):</li><li>\u2022 long-term maintenance therapy to prevent recurrence of depressive episodes</li><li>\u2022 Option D. Tricyclic antidepressants (TCAs): TCAs are another class of antidepressants that can be used for long-term maintenance therapy in recurrent depressive disorder , although they are often less preferred than SSRIs due to their side effect profile.</li><li>\u2022 Option D. Tricyclic antidepressants (TCAs):</li><li>\u2022 class of antidepressants that can be used for long-term maintenance therapy</li><li>\u2022 recurrent depressive disorder</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In the context of recurrent depressive disorder, common options for prophylactic therapy include lithium, SSRIs, and TCAs . Valproate , while a mood stabilizer and anticonvulsant, is not typically used for the prevention of recurrent unipolar depressive episodes.</li><li>\u27a4 recurrent depressive disorder, common options for prophylactic therapy include lithium, SSRIs, and TCAs</li><li>\u27a4 Valproate</li><li>\u27a4 mood stabilizer and anticonvulsant, is not typically used</li><li>\u27a4 Ref : Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 388-391.</li><li>\u27a4 Ref : Kaplan & Sadock\u2019s Synopsis of Psychiatry, 12th edition, Page No 388-391.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b5716f4b",
      "audio": ""
    }
  ]
}